Evaluating the effectiveness of Aspirin in Colorectal Cancer patients in terms of disease free survival and overall survival.

Interventions: An eligible subject will be randomised to the study in 1:1 ratio to either
- Aspirin arm: 200 mg Aspirin once a day for 3 years
- Placebo arm: 200 mg matching placebo once a day for 3 years.
After randomisation, patient will have 3 monthly assessments for 3 years (month 3 to month 36) followed by 6 monthly assessments for additional 2 years (month 42 to month 60). Assessments include Haematology, Biochemistry, Colonoscopy, CT Scan, X-ray, ECG).
Primary outcome(s): 1.Disease free survival (DFS) among all eligible subjects (high risk Dukes B colon cancer, Dukes C colon cancer and rectal cancer patient sub-groups)
2.DFS among patients with colon cancer (high-risk Dukes B and Dukes C colon cancer)
[From randomization up to 5 years (3 monthly assessments for 3 years followed by 6 monthly assessments for additional 2 years)]
Study Design: Randomized controlled trial